Matches in UGent Biblio for { <https://biblio.ugent.be/publication/2048303#aggregation> ?p ?o. }
Showing items 1 to 37 of
37
with 100 items per page.
- aggregation classification "A1".
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation date "2012".
- aggregation format "application/pdf".
- aggregation hasFormat 2048303.bibtex.
- aggregation hasFormat 2048303.csv.
- aggregation hasFormat 2048303.dc.
- aggregation hasFormat 2048303.didl.
- aggregation hasFormat 2048303.doc.
- aggregation hasFormat 2048303.json.
- aggregation hasFormat 2048303.mets.
- aggregation hasFormat 2048303.mods.
- aggregation hasFormat 2048303.rdf.
- aggregation hasFormat 2048303.ris.
- aggregation hasFormat 2048303.txt.
- aggregation hasFormat 2048303.xls.
- aggregation hasFormat 2048303.yaml.
- aggregation isPartOf urn:issn:1068-9265.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer".
- aggregation abstract "Limited data are available on the use of cytoreductive surgery with hyperthermic intraperitoneal chemoperfusion (HIPEC) in patients with recurrent stage III ovarian cancer. Patients with recurrent, heavily pretreated ovarian cancer were enrolled onto a phase II multimodal protocol consisting of extensive cytoreduction followed by HIPEC. Forty-two women were treated from October 2002 until January 2009. Chemoperfusion was performed with cisplatin in 59% and oxaliplatin in 41% of patients. A macroscopically complete resection was achieved in 50% of patients. No mortality occurred, and the major morbidity rate was 21%. After a mean follow-up of 21 months, median overall survival (OS) was 37 months (95% confidence interval 12.2-61.8) and median progression-free survival was 13 months (95% confidence interval 6.9-19.1). In univariate analysis, OS was influenced by completeness of cytoreduction, type of chemoperfusion drug, nodal status, and tumor grade. In a Cox regression model, only completeness of cytoreduction (hazard ratio 0.06-0.8, P = .022) and tumor grade (hazard ratio 1.23-12.6, P = .021) were independent predictors of OS. In selected patients with heavily pretreated recurrent ovarian cancer, cytoreduction combined with HIPEC may provide a meaningful OS with acceptable morbidity. Optimal results are achieved in patients with a macroscopically complete resection and biologically favorable disease.".
- aggregation authorList BK777699.
- aggregation endPage "2359".
- aggregation issue "7".
- aggregation startPage "2352".
- aggregation volume "19".
- aggregation aggregates 2072829.
- aggregation aggregates 2996420.
- aggregation isDescribedBy 2048303.
- aggregation similarTo s10434-009-0878-6.
- aggregation similarTo LU-2048303.